RxDoctor Payments Data

Mateen Awan, MD

Internal Medicine · Columbia, MDNPI 1316918303

Payments from drug & device makers

$535in general payments, 2019–2025

Across 6 payments — averaging $89.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$133
  • Bayer$132
  • Dexcom, Inc.$120
  • AstraZeneca$115
  • Acadia Pharmaceuticals Inc$34

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk2$133
Bayer1$132
Dexcom, Inc.1$120
AstraZeneca1$115
Acadia Pharmaceuticals Inc1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$535 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$368,748
Medicare patients
479
Services billed
3,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban326$149,293
JardianceEmpagliflozin139$91,737
DovatoDolutegravir Sodium/Lamivudine15$39,287
JanuviaSitagliptin Phosphate50$35,060
OzempicSemaglutide13$23,384
EntrestoSacubitril/Valsartan18$16,649
XareltoRivaroxaban38$15,468
JanumetSitagliptin Phos/Metformin Hcl11$15,280
WegovySemaglutide11$14,583
Atorvastatin Calcium736$13,163
Imatinib Mesylate12$10,229
Divalproex Sodium149$9,073
FarxigaDapagliflozin Propanediol18$9,059
NamzaricMemantine Hcl/Donepezil Hcl12$7,434
TrulicityDulaglutide14$6,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$133$37,96724 claims
AstraZenecaFarxiga$115$9,05918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →